Amgen to invest $900m in Ohio manufacturing facility
Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.
The move brings the total investment in Central Ohio to more than $1.4bn, and the total number of national employment opportunities created to 750.
The expansion is part of the company's strategy to enhance its manufacturing offerings in the US.
It first established its presence in the Ohio region in June 2021 with the announcement of a biomanufacturing facility in the Columbus Region, generating 400 employment opportunities.
In February 2024, the company opened the 300,000 ft² Ohio facility to meet the growing demand for its medications within the country.
Following the Tax Cuts and Jobs Act of 2017, Amgen has made substantial investments in the US.
It has invested almost $5bn in direct capital expenditures, contributing an additional $12bn in downstream output to the country's economy.
The Ohio expansion is part of Amgen's worldwide biomanufacturing network, which benefits from operational expertise and technological advancements.
The investments across the US align with the company's focus on establishing biologics manufacturing capabilities globally.
Amgen CEO and chairman Robert Bradway stated: "Today's investment reinforces our ongoing commitment to expanding US manufacturing and ensuring patients around the world have access to our innovative medicines.
"Ohio offers a supportive business climate, skilled workforce and strategic location, making it an ideal choice for this next phase of our investment."
In January 2025, Amgen inaugurated a new drug substance facility in the US after announcing a further $1bn expansion at its North Carolina site.
"Amgen to invest $900m in Ohio manufacturing facility" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.
Yahoo
2 days ago
- Yahoo
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed every year and 200,000 deaths occurring. With such a high healthcare burden, rapid advancements have been made with the advent of programmed cell death protein-1 checkpoint inhibition and immunotherapy, although they have only been proven successful in the first-line paradigm. Unlike non-small cell lung cancer (NSCLC), the treatment options for SCLC are more limited, as it is more aggressive and develops resistance to available treatments rapidly. One of the current standards of care (SOC) is the use of platinum-based chemotherapy such as cisplatin in combination with Roche's Tecentriq or AstraZeneca's Imfinzi in the first-line treatment for extensive-stage SCLC (ES-SCLC). Following treatment, many patients with NSCLC will develop platinum resistance through strengthened DNA-repair capabilities and reduced chemotherapy uptake in the cancerous cells. Amgen's Imdelltra, a bispecific T-cell engager (BiTE) that targets Delta-like canonical Notch ligand 3 (DLL3) and cluster of differentiation 3 (CD3) receptors, received US Food and Drug Administration approval for the treatment of patients with ES-SCLC following disease progression or following platinum-based chemotherapy, based on results from the DeLLphi-301 trial. While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted as DeLLphi-301 was a Phase II trial with only one arm and no comparator. Results from the American Society of Clinical Oncology 2025 have shown the latest in Imdelltra's clinical results from the DeLLphi-304 trial. DeLLphi-304 enrolled 254 patients receiving Imdelltra and 255 receiving one of the following: topotecan, amrubicin, or Jazz Pharmaceutical's Zepzelca. Zepzelca and topotecan are preferred systemic treatment options for SCLC. Imdelltra was found to increase overall survival by 5.3 months (hazard ratio: 0.60, P<0.001) and increase median progression-free survival. There was also a large difference in grade 3 treatment-related adverse events, with Imdelltra reducing the rate by 35% compared to the control arm. Absent any competing immunotherapies with a preferred National Comprehensive Cancer Network opinion, Imdelltra is expected to be an attractive option for many patients looking to enhance their care. The annual cost of Imdelltra therapy totals $167,600 per patient. As a result, Imdelltra will likely struggle to receive reimbursement outside of the US. Despite the high cost, the clinical benefits are clear and Imdelltra's US market share uptake will be enhanced with these positive results, particularly owing to its more manageable safety profile when compared to existing options for this segment. Leading data and analytics company GlobalData's indication-based forecast shows Imdelltra will reach $1.76bn globally by 2031. "ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Chicken Salad Chick to open ten new restaurants in Minneapolis
US-based fast casual restaurant Chicken Salad Chick is broadening its footprint in the Midwest with ten new restaurants in the Minneapolis area. This is a significant step for the brand as it introduces its dining experience to the Upper Midwest. The Coffey family, with a basketball legacy, is behind the signed agreement that will bring the franchise to the region. Richard Coffey said: "We knew we wanted to go into business with a brand that we could all get behind. "Chicken Salad Chick stood out because of the support and communication we've received from the team. This is more than a business venture, it's a family journey, and we're excited to do it with a brand that feels the same way." The brand's strategic growth plan includes opening the ten locations before 2030, targeting development in Hennepin and Ramsey County. With an open real estate landscape, Chicken Salad Chick sees opportunities for market growth in the Midwest. Franchise development vice-president Mark Verges stated: "We're thrilled to have a passionate and community-driven family join Chicken Salad Chick. "Their deep roots in Minnesota and commitment to giving back make them great partners as we grow our presence in the Midwest." Chicken Salad Chick is leveraging the momentum from 2024, aiming to set new records with franchise deals across the US in 2025. The franchise development team has identified Illinois, Iowa, Michigan, Minnesota, Ohio, Pennsylvania, West Virginia and Wisconsin as key areas for growth. The brand has experienced a 13% increase in unit count year-on-year and reports more than $400m in system-wide sales, a 56% increase over 2021, with an average unit volume (AUV) of $1.48m, according to its 2024 franchise disclosure document (FDD). In addition to the Midwest expansion, Chicken Salad Chick recently announced plans to increase its presence in Texas with a new outlet in Temple. "Chicken Salad Chick to open ten new restaurants in Minneapolis" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
